- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
Patent holdings for IPC class C07D 213/71
Total number of patents in this class: 410
10-year publication summary
35
|
45
|
36
|
38
|
40
|
33
|
16
|
34
|
17
|
6
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Sumitomo Chemical Company, Limited | 9031 |
19 |
Amgen Inc. | 4071 |
13 |
ImmunoGen, Inc. | 399 |
13 |
Novartis AG | 10886 |
11 |
Bristol-myers Squibb Company | 4879 |
9 |
F. Hoffmann-La Roche AG | 7934 |
9 |
Takeda Pharmaceutical Company Limited | 2712 |
9 |
The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 163 |
7 |
Ube Industries, Ltd. | 852 |
7 |
The University of Queensland | 658 |
7 |
Arcus Biosciences, Inc. | 137 |
6 |
Inflazome Limited | 85 |
6 |
Oxford Drug Design Limited | 9 |
6 |
The Johns Hopkins University | 5652 |
5 |
Cardioxyl Pharmaceuticals, Inc. | 49 |
5 |
Sanofi | 4036 |
5 |
BASF SE | 20892 |
4 |
Syngenta Crop Protection AG | 6049 |
4 |
Board of Regents, The University of Texas System | 5763 |
4 |
Baylor College of Medicine | 943 |
4 |
Other owners | 257 |